07.23.24 -- Drug Development Needs More Focus On Profitability

Not really into choosing extended time away and exhibit halls over the simple pleasures of summertime? No reason to put your CDMO search on hold – Outsourced Pharma Capacity Update’s PARTNER WEEK is here! Take the travel and headache out of your plans and join us right from your computer. Assess potential fit for your next drug development project in convenient 20-minute segments – all grouped by molecule type. Presenters will share current available capacity across featured capabilities. Register for free.

This article describes strategies for scaling up production of CAR-T products, including the hub model, bedside model, innovation of process strategy, and more.

Vincent Kosewski, VP at Kala Pharmaceuticals, believes there’s a gap when it comes to biotechs performing the necessary gap analysis before initiating outsourcing activities.

Manufacturing mRNA products is a complex and challenging process that requires careful consideration at each stage. Learn more about the challenges and intricacies involved.

As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology.

Delve into the current challenges and opportunities of therapeutic targets, manufacturing processes, and regulatory frameworks for CGTs and realize the full potential of these revolutionary therapies.

In this study, we evaluated the performance of two dbDNA IVT templates, each encoding the same mRNA (firefly luciferase or Fluc), by looking at the mRNA purity and in vivo potency of the mRNA IVT’d from each template.

Build a reliable, de-risked path to the clinic while avoiding unforeseen costs and compliance-related delays with advice from an industry expert.

Validated processing methods and storage conditions are the first steps towards providing a safe and effective product. Review a retrospective analysis of a final verification process.

Learn about a validated dry ice shipping system that fills a critical gap in the life sciences industry and is revolutionizing the transport of high-value commodities.

Extracellular vesicles hold immense potential for treating diseases, owing to their natural biocompatibility and ability to carry a diverse arsenal of therapeutic molecules.

What's your development and manufacturing outsourcing strategy based on? Do you have the right contracts and external relationships in place to successfully implement that strategy? Are there new models for sponsor-CDMO partnerships? Join Outsourced Pharma Live on August 13th as our panel of professionals will provide personal analysis and ideas for determining how you might best conduct your development and manufacturing activities, outsourcing business models, and external relationships.

Learn how we are advancing novel programs internally and enabling partners in their development of next-generation therapies for otherwise intractable diseases.

This demonstration examines an AAV upstream process in proprietary bioreactors, including an example of using process optimization to increase the fraction of full AAV capsids.

We deliver total solutions that facilitate process development and GMP manufacturing of innovative CGT products, enabling our clients to expedite their products to market.